Pharmacological management of Osteomyelitis

dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.contributor.authorSackey, Wilhelmina
dc.contributor.departmentDE--Általános Orvostudományi Kar
dc.contributor.opponentHalasi , Barbara
dc.contributor.opponentMegyeri , Attila
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Igazságügyi Orvostani Intézet
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet
dc.description.abstractOsteomyelitis can be described as an inflammatory condition of the bone and its supporting components that develops as a result of an infectious process mostly caused by pyogenic microorganisms. It is diagnosed clinically, based on constitutional symptoms, however bone biopsy with histopathological examination and tissue culture, remains the gold standard. Management involves use of prolonged antimicrobial therapy with beta lactams being the most often used antibiotics as first line therapy. Additional therapies include the use of tetracyclines, fluoroquinolones, clindamycin and glycopeptides. It is critical to note that newer medications such as oritavancin and dalbavancin are quite effective in treating certain resistant strains. Biologic treatment and nonsteroidal anti-inflammatory drugs (NSAIDs) are also used in concert with antibiotics to alleviate pain and diminish the inflammatory response. Overall, osteomyelitis has a good prognosis if robust antibiotic therapy is started as soon as possible.
dc.description.courseáltalános orvos
dc.description.degreeegységes, osztatlan
dc.rights.accessHozzáférhető a 2022 decemberi felsőoktatási törvénymódosítás értelmében.
dc.subjectPyogenic organisms
dc.subjectStaphylococcus Aureus
dc.subject.dspaceDEENK Témalista::Orvostudomány::Farmakológia
dc.titlePharmacological management of Osteomyelitis